Frequently Asked Questions

The PSP is Limitless Consulting’s flagship initiative for self-funded employers designed to identify and correct pharmacy waste within existing health-plan structures.

The program focuses on optimized sourcing by isolating the 1 to 2% of medications that drive the majority of total prescription spend and determining the lowest legal and compliant cost to obtain those same medications. The focus is not utilization management or formulary redesign. It is correcting price distortion at the point of acquisition.

Limitless has curated and maintains a certified national vendor network designed to ensure quality, safety, legal compliance, and defensible pricing. Vendors are selected, vetted, and contractually bound to meet Good Manufacturing Practice standards, documented chain-of-custody requirements, dispensing controls, and prescription verification. This curated structure allows Limitless to secure nationally negotiated rates and conduct competitive, claims-specific sourcing on behalf of each employer.

In practice, the PSP reclaims approximately 50 to 80% of unnecessary spend on high-cost medications while maintaining full regulatory compliance and zero disruption to existing PBMs, carriers, provider networks, or plan design.

The PSP relies on the same safety and quality laws as the entire U.S. prescription drug system.  In U.S. law, drug safety is defined by Good Manufacturing Practice.

Federal statute 21 U.S.C. § 351(a)(2)(B) and implementing regulations at 21 C.F.R. Parts 210 and 211 establish GMP as the controlling quality standard for all prescription drugs used in the United States. These requirements apply equally to domestic and foreign manufacturers. The statute makes no distinction based on country of origin.

More than 80% of active pharmaceutical ingredients used in U.S. prescription drugs are manufactured outside the United States under GMP standards. The FDA already relies on foreign GMP compliance to sustain the domestic drug supply.

If GMP equivalence were insufficient to ensure safety, the U.S. prescription drug system would not function.

The PSP does not introduce a new safety standard, but instead relies on the same one the FDA already enforces across the global supply chain.

Yes.   FDA oversight of importation is governed by enforcement authority under 21 U.S.C. § 381(a). For decades, FDA has allowed personal-use prescription importation for millions of Americans and tens of thousands of employers, when defined criteria are met. These criteria include a valid prescription, personal use quantities, no resale, legitimate sourcing, and documented chain of custody.

The PSP adheres to those criteria as a matter of program design.

Importantly,  PSP vendors are contractually certified and operationally vetted for GMP manufacturing, documented chain of custody, temperature control, dispensing integrity, and prescription verification. PSP vendors operate without FDA warning letters, import alerts, seizures, or enforcement actions. If there were compliance issues, there would already be an enforcement record. There is none.

FDA discretion in the context of prescription drug importation does not exist to evaluate drug safety or quality. Those questions are already answered by statute.

Drug safety and quality are governed by Good Manufacturing Practice under federal law. If a drug is manufactured in compliance with GMP and maintained through a documented chain of custody, it meets the statutory safety standard. That is true regardless of where the drug is manufactured. Without this principle, the U.S. pharmaceutical system would cease to function, because the FDA already relies on foreign GMP compliance for the majority of the U.S. drug supply.

FDA discretion exists for whether an importation event constitutes personal use or impermissible commercial distribution.

Under 21 U.S.C. § 381(a), Congress granted the Food and Drug Administration authority to admit or refuse drugs offered for import. FDA exercises that authority to prevent drugs from being introduced into U.S. commerce outside the approved commercial distribution system. That is the purpose of discretion. 

If a medication has followed GMP and chain of custody, the dividing line FDA evaluates is commerce, and a transaction is treated as personal use when the following conditions are met:

💊 The drug is dispensed pursuant to a valid prescription
💊 The drug is imported for an individual patient’s personal use
💊 The patient is the importer of record
💊 There is no resale, redistribution, or re entry into U.S. commercial channels

When those conditions are satisfied, the importation does not constitute commercial importation as a matter of law or enforcement practice.

The PSP is structured to meet these conditions by design. Each prescription is patient specific. Each shipment is patient specific. The patient remains the importer of record. There is no inventory pooling, resale, or plan level ownership of drugs. The program never introduces drugs into U.S. commerce.

In some cases, yes. Rebates may be reduced on certain high-cost medications. That concern is understandable, but it misunderstands how rebates function economically.

Rebates exist only because the underlying drug price is inflated. They are a partial giveback of an artificially high price, not a source of true savings. When the underlying price drops to a market-based level, the rebate attached to the inflated price disappears because it no longer serves a purpose.

The economics are straightforward. Paying $800 per medication and receiving a $100 rebate still results in a $700 net cost. Paying $200 per unit with no rebate results in a $200 net cost. The rebate is irrelevant once the underlying price distortion is removed.

All PSP analyses are calculated on a net basis. Any rebate reduction is explicitly deducted before savings are presented. The relevant question is not whether a rebate is reduced. The relevant question is whether total net cost decreases. Under the Pharmacy Stewardship Program, it does, consistently.

No. The PSP is designed to operate alongside your existing structure without disruption. Your insurance carrier remains unchanged, your PBM, provider networks, formularies, consultant, and plan design remain intact. There is no replacement, carve-out, or renegotiation required.

The PSP functions as a voluntary, out-of-cycle overlay that applies only to a limited set of high-cost prescriptions. Participation is optional for members and reversible for the employer. All other prescriptions continue to flow through the PBM exactly as they do today.

There are no changes to provider relationships, referral patterns, or clinical decision-making. Prescriptions remain written by the same physicians and dispensed pursuant to valid prescriptions. The only difference is the sourcing channel for a small % of medications where lower, compliant pricing is available.

From an operational standpoint, Limitless and our vendor network manages implementation, member outreach, coordination, and documentation. Existing vendors are not displaced, and existing contracts are not disturbed.

No. The PSP is designed to operate without adding administrative burden or internal headcount.

Limitless manages the end-to-end process through its curated vendor network, including claims analysis, vendor coordination, implementation, member outreach, prescription validation, fulfillment oversight, and ongoing support. Employers are not required to build new workflows, assign internal staff, or manage day-to-day operations.

The PSP integrates into existing benefit administration processes and runs outside renewal cycles. Participation is voluntary for members, and employer involvement is limited to oversight and reporting.

The PSP functions as a turnkey overlay delivered through a certified vendor network, providing measurable results without increasing workload or requiring additional personnel.

No. For participating members, the PSP is designed to reduce friction rather than add it.

Prescriptions remain written by the same physicians. The medication remains the same. There are no changes to provider access, clinical decision-making, or plan eligibility. Participation is voluntary, and employees who choose not to participate continue using the plan exactly as they do today.

For those who participate, the PSP typically simplifies the experience. Medications are delivered directly to the employee’s home through the certified vendor network, with coordinated support to manage onboarding, refills, and questions. Out-of-pocket costs are often reduced or eliminated.

From the employee’s perspective, the PSP replaces a high-cost pharmacy transaction with a lower-cost, home-delivery option, without added steps or administrative burden.

Because the pharmacy market is highly concentrated, and the dominant players benefit from keeping alternative sourcing mechanisms out of view, or malign all competitive offerings with misinformation or inaccurate descriptions.

3 PBMs control roughly 80% of prescription drug claims in the U.S. and influence nearly every step of the supply chain, including pricing, formularies, specialty pharmacies, rebate structures, and data access. Their economic model depends on maintaining high list prices, opaque pricing mechanics, and rebate-based arrangements that only function when alternative pricing channels remain marginal or misunderstood.

Lower-cost sourcing options threaten that model. When the underlying price of a drug falls, the rebate attached to the inflated price disappears, along with the associated margin. As a result, there is little incentive for incumbent PBMs to educate employers, consultants, or brokers on mechanisms that reduce net drug costs outside their pricing structures.

This market control is reinforced through one of the most effective lobbying networks in healthcare. PBMs and aligned pharmaceutical interests invest heavily in shaping policy narratives, regulatory caution, and public messaging around drug sourcing. The result is persistent emphasis on perceived risk, complexity, or uncertainty, even when existing law and FDA enforcement practice already allow compliant alternatives.

The PSP has existed in practice for years, but it has largely remained outside mainstream benefits conversations because it does not align with incumbent incentives. It operates quietly, focuses on a small % of high-cost claims, and delivers results without changing carriers, PBMs, or plan design. That combination makes it effective for employers and unappealing for those who profit from the current structure.

In short, the reason most employers have not heard of the PSP is not because it is new or unproven. It is because the current system does not reward visibility into options that reduce its own margins.

That response is common, but it is often misleading.

In many cases, objections are raised because programs like the PSP disrupt existing pricing and revenue structures, not because they violate federal law. Those are business objections framed as compliance concerns. They should be evaluated as such.

PBMs and carriers issue guidance based on their contracts, internal policies, and economic incentives. That guidance does not determine legality. Legal authority comes from statute and FDA enforcement practice. PBMs and carriers do not have regulatory authority to prohibit lawful activity outside their own pricing channels.

For self-funded employers, plan sponsors retain discretion to offer compliant options outside the PBM’s network. You are not bound to your PBM’s opinion or pricing model when implementing lawful strategies that operate alongside the existing plan. The PSP does not require PBM or carrier approval. It does not alter plan design, formulary structure, or provider networks. Existing arrangements remain intact.

The PSP provides members with a legal, voluntary pathway to access select high-cost medications through compliant sourcing at substantially lower cost. Participation is optional. Nothing is forced into the plan.

From a fiduciary standpoint, this is a critical distinction. ERISA requires plan fiduciaries to act prudently and in the interest of participants. Recent litigation, including high-profile cases against large employers, has focused on whether fiduciaries failed to evaluate available cost-reduction options. The risk environment has shifted. Ignoring lawful alternatives now carries its own exposure.

When a vendor asserts something “isn’t allowed,” the appropriate question is straightforward: what statute, regulation, or FDA enforcement action prohibits it?

In practice, those citations are rarely produced. What remains are contractual preferences and economic concerns. Employers retain the authority to evaluate and implement compliant options that reduce cost without cutting benefits.

For self-funded health plans, access occurs through the PSP once TrumpRx becomes operational.

TrumpRx pricing is not a retail option and cannot be activated inside an existing PBM contract. It requires plan-level implementation to ensure prescriptions are identified, validated, sourced, and fulfilled through compliant channels.

Limitless and our vendor network is uniquely positioned to offer access through the PSP because the required infrastructure is already in place.

Once implemented, eligible prescriptions can access TrumpRx pricing on a voluntary, out-of-cycle basis without changing the carrier, PBM, or plan design. Employees do not enroll independently. Access is administered through the plan to ensure compliance and proper oversight.

To perform a savings analysis we only need a standard 12-month pharmacy claims file that is already available from your PBM. This file is de-identified and does not contain personal health information. It shows the drug name, quantity, and cost... nothing more. Data is transferred securely using encrypted channels, and our team handles the entire setup process so there is no added burden on your IT or HR staff. The process is simple, fast, and fully compliant with federal privacy and security requirements.

The pharmacy market is evolving quickly, with new direct-to-consumer and manufacturer-sponsored programs entering the space. Employers should not have to chase these opportunities on their own. Limitless monitors, validates, and integrates new pathways as they become available, ensuring that our clients are always capturing the best prices in a compliant and seamless way. Whether it is TrumpRx or other Most Favored Nation style initiatives, our role is to stay at the forefront and bring those options into your plan so that you do not miss out on future savings. 

By correcting price distortion rather than reducing access.

For self-funded plans, the largest cost increases are driven by a small set of high-cost services and medications priced far above their underlying market value. Employers lower costs when they address how those services are priced and sourced, not by narrowing coverage, increasing deductibles, or shifting cost to employees.

In pharmacy, the leverage point is the 1 to 2% of prescriptions that drive roughly 50% of total spend. When those medications are obtained through compliant, lower-cost channels, the plan pays less for the same drug, prescribed by the same physician, with the same clinical outcome. Coverage stays intact. Benefits remain unchanged.

The same principle applies more broadly. Costs decline when employers introduce transparency, alternative sourcing, and claims-level controls that remove inflated pricing from the system. This approach reduces waste embedded in the supply chain rather than restricting care.

Plans that lower costs without cutting benefits focus on price correction, not benefit reduction. The PSP is designed around that principle.

The primary driver of rising employer healthcare costs is pharmacy spend, not utilization. Specialty medications and biologics now account for a disproportionate share of total plan costs, often driven by pricing mechanics rather than clinical necessity. Administrative complexity, rebate structures, and opaque pricing models further accelerate year-over-year increases. 

The biggest opportunity is pharmacy spend, particularly the 1 to 2% of medications that drive 40 to 60% of total prescription costs. Medical costs are difficult to influence without network disruption, but pharmacy costs can often be reduced materially through compliant sourcing and optimization strategies that operate outside the core insurance contract. 

Most self-funded employers can expect to save approximately $1 million to $1.5 million per 1,000 employees annually when high-cost pharmacy waste is addressed. These savings are net of rebates and do not require benefit reductions or vendor replacement. Actual results depend on plan size, utilization, and drug mix. 

Yes. For self-funded health plans, cost reductions can be implemented at any point during the plan year.

Self-funded employers are not locked into annual renewal cycles for all cost-control actions. While carrier pricing and some administrative terms reset at renewal, many cost drivers, especially pharmacy spend, operate on a claims-paid basis and can be addressed in real time.

Programs like the PSP are implemented out-of-cycle because they do not require changes to the carrier, PBM contract, provider networks, or plan design. They operate as overlays to the existing structure and apply only to specific high-cost claims as they occur.

As a result, savings begin when claims are redirected through the program, not at renewal. There is no need to wait 6 to 12 months while costs continue to accrue.

In practical terms, employers with self-funded plans can reduce pharmacy costs during the plan year when a compliant, operational mechanism exists to do so. The PSP is designed for that purpose.

Most traditional strategies focus on cost shifting rather than cost reduction. Higher deductibles, narrower networks, and formulary restrictions often reduce employer liability while increasing employee burden. These approaches do not address the underlying pricing inefficiencies driving pharmacy costs and often create dissatisfaction without meaningful long-term savings. 

This approach is applicable for self-funded employers of all sizes, where pharmacy utilization patterns create savings opportunities. Smaller employers may still benefit, but results scale with population size and the presence of high-cost specialty medications. We're happy to provide case studies of employers of a similar size and industry so you can know what to reasonably expect for an outcome.

Savings begin immediately after implementation. Unlike multi-year cost-containment strategies, pharmacy optimization delivers measurable impact quickly. 

No. Prescription drug importation is lawful under federal law when it meets defined requirements. The PSP is designed to follow these requirements precisely.

Congress expressly gave the Food and Drug Administration authority to regulate and permit prescription drug importation under 21 U.S.C. § 381(a). Under that authority, FDA has long allowed personal-use prescription importation when specific conditions are satisfied. This framework has been in place for decades and is actively applied in routine enforcement.

Federal law treats prescription drug importation as a regulated activity. FDA’s role is to determine whether an importation event qualifies as personal use or constitutes impermissible commercial distribution. When a drug is imported pursuant to a valid prescription, for an individual patient’s personal use, with no resale and proper sourcing, it is permitted under existing federal authority.

Congress reinforced this treatment by enacting 21 U.S.C. § 384, which addresses regulated importation as a lawful mechanism subject to safety and oversight requirements. That statute exists because importation is lawful when structured correctly.

Prescription drug importation becomes unlawful only when it crosses into commercial resale, introduces adulterated or misbranded drugs, or fails to meet FDA’s personal-use criteria. When those criteria are met, importation is permitted as a matter of law and enforcement practice.

No. That statement is incorrect and conflates two different regulatory concepts.

FDA approval applies to drugs introduced into U.S. commercial distribution. Personal-use importation operates under a separate legal and enforcement framework. The FDA does not “approve” personal-use importation because approval is not the mechanism that governs it.

Congress gave the Food and Drug Administration authority under 21 U.S.C. § 381(a) to regulate and permit prescription drug importation. Under that authority, FDA has long allowed personal-use prescription importation when defined criteria are met. This framework has existed for decades and is actively applied in routine enforcement.

The purpose of FDA review in personal-use importation is to determine whether a transaction qualifies as personal use or constitutes commercial distribution. It is not a safety approval process. Safety and quality are already governed by Good Manufacturing Practice and chain-of-custody requirements.

“Not FDA-approved” in this context means the drug is not being introduced into U.S. commercial channels under a New Drug Application or Biologics License Application. It does not mean the importation is unlawful. If lack of FDA approval automatically rendered personal importation illegal, FDA could not lawfully allow it, and Congress would not have enacted statutory provisions addressing regulated importation.

Illegality arises only when importation involves resale, commercial distribution, adulteration, misbranding, or failure to meet personal-use criteria. When those criteria are satisfied, personal-use importation is permitted under federal law and FDA enforcement practice.

Statements equating “not FDA-approved” with “illegal” misstate how federal drug law works and are commonly used to discourage evaluation of lawful alternatives.

No. That statement misstates how federal drug law defines commercial importation.

Under federal law, importation is classified based on the structure of the transaction, not on who pays for it or facilitates it. The legal distinction turns on whether a drug is introduced into U.S. commercial distribution through resale or redistribution.

Employer involvement does not convert personal-use importation into commercial importation when the following conditions are met:

💊 The medication is dispensed pursuant to a valid prescription

💊 The medication is imported for an individual patient’s personal use

💊 The patient is the importer of record

💊 There is no resale, redistribution, inventory pooling, or plan-level ownership

💊 The drug does not enter U.S. commercial channels

Those conditions define personal-use importation as a matter of law and enforcement practice.

Congress granted the Food and Drug Administration authority under 21 U.S.C. § 381(a) to regulate importation and to prevent drugs from being introduced into U.S. commerce outside the approved commercial system. FDA’s role in this context is to evaluate whether an importation event constitutes personal use or commercial distribution. Employer payment or facilitation is not the determining factor.

If employer involvement alone rendered personal importation unlawful, then patient assistance programs, manufacturer bridge programs, employer-funded specialty pharmacies, and third-party fulfillment models would all be impermissible. They are not, because payment and facilitation do not define commerce. Resale does.

Personal importation becomes unlawful only when drugs are resold, redistributed, pooled, or otherwise introduced into U.S. commercial distribution. When the patient remains the importer of record and the medication is dispensed for personal use, employer sponsorship does not alter the legal classification.

The PSP is structured to preserve this distinction by design.

By implementing a documented, data-driven process to understand pharmacy costs, evaluate lawful alternatives, and demonstrate informed decision-making.

Recent ERISA litigation has focused less on outcomes and more on process. In high-profile cases involving large employers, the central issue was whether fiduciaries accessed claims and financial data, understood how pharmacy costs were structured, and evaluated available options rather than defaulting to opaque PBM arrangements.

Under ERISA, fiduciaries are expected to act with care, skill, prudence, and diligence based on the circumstances then prevailing. That standard requires active oversight, not passive reliance on vendor assurances.

The C-PSP framework was designed specifically to address this exposure. It provides a structured approach for identifying high-cost drivers, pricing alternatives on a net basis, evaluating compliant sourcing options, and documenting the analysis and resulting decisions. The framework does not require adoption of any specific solution. It requires evaluation and documentation.

This approach aligns directly with current regulatory guidance from the Department of Labor, which has emphasized that PBM pricing, compensation structures, and data transparency are fiduciary concerns. In this environment, risk is reduced when fiduciaries can demonstrate that they understood the cost drivers, considered available alternatives, and made informed decisions supported by data.

For a CFO, the objective is not to chase savings in isolation. It is to ensure that the plan’s largest cost categories are actively governed, reviewed, and documented in a way that withstands fiduciary scrutiny.